Abstract 670P
Background
DLL3 is expressed on many cancers, including small-cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinomas (epNECs), and large cell neuroendocrine carcinoma of the lung (LCNEC). BI 764532 is a DLL3/CD3 IgG-like T cell engager that initiates T cell-mediated immune responses against DLL3+ tumors. NCT04429087 is a Phase I trial of BI 764532 in pts with DLL3+ SCLC, epNECs or LCNEC.
Methods
Escalating doses of BI 764532 were given IV in 4 regimens: RA (fixed dose q3w); RB1 (fixed dose qw); RB2 and RB3 (step-in dose, then target dose). Treatment (Tx) continued until progression, unacceptable toxicity, other withdrawal criteria, or for 36 months (mos) maximum. Primary objective: determine MTD and/or RDE of BI 764532. Other objectives: safety; tolerability; PK/PD; preliminary efficacy (investigator-assessed; RECIST 1.1).
Results
As of Feb 21, 2024, 168 pts had ≥1 dose of BI 764532 (RA: n=24; RB1: n=10; RB2: n=79; RB3: n=55). Median age: 61 yrs (range 32–81); ECOG PS 0/1/missing: 27/67/5%; prior PD1/PD-L1 Tx: 51%; ≥2 prior lines of Tx: 72%. SCLC/epNEC/LCNEC: 49/42/8%. 6 pts experienced DLTs during the MTD evaluation period (all on RB2): G4 CRS; G3 CRS; G5 ICANS; G3 ICANS; G3 nervous system disorder; G2 infusion-related reaction). MTD was not reached. TRAEs (any/G3+): overall 88/24%; RA 79/21%; RB1 60/20%; RB2 96/34%; RB3 86/11%. Most common TRAEs were (any/G3+): CRS (57/3%); dysgeusia (23/0%); pyrexia (21/0%); asthenia (20/1%). With RB2/RB3, most CRS and neurological events occurred early, and were reversible. Unconfirmed tumor response data are shown below. Efficacy was highest with RB2/RB3 where all pts received target doses of ≥90 μg/kg. Overall, median DoR (95% CI): 8.5 mos (6.2—NR); estimated 6-mo DoR: 70%. 23/38 responding pts are still on Tx. Median PFS (95% CI): 1.5 mos (1.4-2.4); estimated 6-mo PFS: 20%.
Conclusions
BI 764532 showed clinically manageable tolerability and promising efficacy in SCLC, epNEC and LCNEC. Table: 670P
SCLC ORR/DCR, % | n | epNEC ORR/DCR, % | n | LCNEC ORR/DCR, % | n | All ORR/DCR, % | n | |
RA | 7/20 | 15 | 14/29 | 7 | 0/50 | 2 | 8/25 | 24 |
RB1 | 0/0 | 4 | 0/20 | 5 | 0/0 | 1 | 0/10 | 10 |
RB2 | 22/44 | 41 | 22/41 | 32 | 83/100 | 6 | 27/47 | 79 |
RB3† | 20/40 | 20 | 31/50 | 26 | 50/75 | 4 | 29/49 | 51 |
Total | 18/36 | 80 | 23/41 | 70 | 54/77 | 13 | 23/42 | 164* |
*Assessable pts started Tx ≥7 wks prior to data cut-off; †tumor type missing in one patient
Clinical trial identification
NCT04429087.
Editorial acknowledgement
Medical writing support for the development of this abstract was provided by Lynn Pritchard, DPhil, of Ashfield MedComms.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
M. Wermke: Financial Interests, Personal, Other, Honoraria: Amgen, Boehringer Ingelheim, Eli Lilly, GWT, Janssen, Merck Serono, Novartis, Synlab; Financial Interests, Personal, Other, Travel/accommodation/expenses: Amgen, AstraZeneca, Bristol Myers Squibb, GEMoaB, Immatics, Merck Serono, Pfizer, Sanofi/Aventis; Financial Interests, Personal and Institutional, Research Funding: Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, ImCheck Therapeutics, Immatics, ISA Pharmaceuticals, Novartis. V. Gambardella: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Genentech, Merck Serono, Roche, Beigen, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Natera, Sierra Oncology, AstraZeneca, Medimmune, BMS, MSD; Financial Interests, Personal, Research Funding: Bayer, Boehringer Ingelheim, Roche. Y. Kuboki: Financial Interests, Personal, Advisory Board: Amgen, Boehringer Ingelheim, Takeda, Incyte, Abbie; Financial Interests, Personal, Other, Honoraria: Eli Lilly Japan, Taiho Pharmaceutical, Takeda; Financial Interests, Institutional, Research Funding: AbbVie, Amgen, Astellas Pharma, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Genmab, Incyte, Ono Pharmaceutical, Taiho Pharmaceutica, Takeda, AstraZeneca, Merck, Novartis, Hengrui. E. Felip: Financial Interests, Personal, Advisory Role: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Genmab, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Turning Point, Daiichi Sankyo; Financial Interests, Personal, Other, independent member of the board: Grifols; Financial Interests, Personal, Speaker’s Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme, Peervoice, Pfizer, Sanofi, Takeda, Touch Oncology. M.F. Sanmamed: Non-Financial Interests, Personal and Institutional, Research Funding: Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Numab; Financial Interests, Personal, Royalties: MSD. O. Alese: Financial Interests, Personal, Advisory Board: Ipsen Pharmaceuticals, Aadi Bioscience, Taiho, Pfizer, Seagen Inc., Bristol Myers Squibb, AstraZeneca, Exelixis, Takeda; Financial Interests, Institutional, Research Grant: Taiho Oncology, Ipsen Pharmaceuticals, GSK, Bristol Myers Squibb, Suzhou Transcenta Therapeutics Co. Ltd., Boehringer Ingelheim, Cue Biopharma, Inc., Merck, Inhibitex Inc, Arcus Biosciences Inc. C.M. Sayehli: Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim; Financial Interests, Personal, Other, Travel/accommodation/expenses: Boehringer Ingelheim, Catalym, Eli Lilly, Ipsen Pharma. E. Arriola Aperribay: Financial Interests, Personal, Other, Honoraria: Takeda, Lilly, Roche, Boehringer Ingelheim, Bristol Myers Squibb, AstraZeneca; Financial Interests, Personal, Other, Travel/accommodation/expenses: Takeda, Roche, MSD, AstraZeneca; Financial Interests, Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: Takeda, Lilly, Roche, MSD, Boehringer Ingelheim, BMS, AstraZeneca. J. Wolf: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, Merck, Mirati, MSD (Merck Sharp & Dohme), Novartis, Nuvalent, Pfizer, Roche, Seattle Genetic, Takeda, Turning Point; Financial Interests, Institutional, Research Funding: BMS, Janssen, Novartis, Pfizer, AstraZeneca. L. Villaruz: Financial Interests, Personal, Advisory Board: Sanofi, Gilead, Johnson and Johnson, Daiichi Sankyo, AstraZeneca; Financial Interests, Personal, Advisory Role: EMD Serono. M. Studeny, M. Bouzaggou, X. Fang: Financial Interests, Personal, Full or part-time Employment: Boehringer Ingelheim. D. Morgensztern: Financial Interests, Personal, Advisory Board: AbbVie, Eli Lilly, Arcus, Mirati; Financial Interests, Personal, Advisory Role: Arcus; Financial Interests, Personal, Principal Investigator: AbbVie, Arcus, Merck, Novartis, Pfizer, Bristol Myers Squibb, Incyte, Surface, Amgen, Genprex, Boehringer Ingelheim, NeoImmunotech, Apollomics.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01